Imatinib stops the progression of chronic myeloid leukemia (CML) by inhibiting BCR-ABL tyrosine kinase, a mutated protein involved in uncontrolled proliferation of leukocytes in patients with CML [4]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.